Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews

Galvão, Taís Freire; Araujo, Maria Elizete A; Penha, Anderson P.; Silva, Marcus Tolentino

doi:10.2174/1871529x14666140401114301

Cited by 3 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of hypertension, DM and dyslipidaemia in patients with CKD can reduce the occurrence of cardiovascular events and improve associated outcomes. 23 Given the links between these diseases, the high proportion of heart and cerebrovascular disease observed in the case group may be expected. In theory, CKD in patients with many comorbidities should progress more rapidly from stage I-IIIa to IIIb than those with fewer comorbidities.…”

Section: Open Accessmentioning

confidence: 99%

Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I–IIIa chronic kidney disease: an observational cohort study in Taiwan

Niu

Chuang

et al. 2021

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo investigate the effect of the Early Chronic Kidney Disease (CKD) Care Programme on CKD progression in patients with CKD stage I–IIIa.DesignObservational cohort study.SettingTaipei Medical University Research Database from three affiliated hospitals.ParticipantsAdult non-pregnant patients with CKD stage I–IIIa from Taipei Medical University Research Database between 1 January 2012 and 31 August 2017 were recruited. These patients were divided into Early CKD Care Programme participants (case) and non-participants (control). The models were matched by age, sex, estimated glomerular filtration rate and CKD stage with 1:2 propensity score to reduce bias between two groups.Outcome measuresThe risks of CKD stage I–IIIa progression to IIIb between Early CKD Care Programme participants and non-participants.ResultsCompared with the control group, the case group demonstrated more comorbidities and higher proportions of hypertension, diabetes mellitus, gout, dyslipidaemia, heart disease and cerebrovascular disease, but had lower risk of progression to CKD stage IIIb before and (HR 0.72; 95% CI 0.61 to 0.85) and after (adjusted HR (aHR) 0.67; 95% CI 0.55 to 0.81) adjustments. Moreover, Kaplan-Meier analysis revealed the cumulative incidence of CKD stage IIIb was significantly lower in the case group than in the control group. Finally, the programme was an independent protective factor against progression to stage IIIb, especially in patients with CKD stage IIIa before (HR 0.72; 95% CI 0.61 to 0.85) and after (aHR 0.67; 95% CI 0.55 to 0.81) adjustments.ConclusionsThe Early CKD Care Programme is an independent protective factor against progression of early CKD.

show abstract

Section: Open Accessmentioning

confidence: 99%

Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I–IIIa chronic kidney disease: an observational cohort study in Taiwan

Niu

Chuang

et al. 2021

BMJ Open

View full text Add to dashboard Cite

show abstract

“…The multitude of interactions between serum lipids and the axis of renal inflammation and fibrosis have made modulation of lipid metabolism and reduction of non‐HDL lipoproteins a primary therapeutic target in the management of CKD in people . Lipid‐lowering statins decrease the incidence of cardiovascular disease, myocardial infarctions, and strokes in people with renal disease . Statins are also under investigation in human patients as agents to decrease renal injury .…”

Section: Discussionmentioning

confidence: 99%

“…1 Lipid-lowering statins decrease the incidence of cardiovascular disease, myocardial infarctions, and strokes in people with renal disease. 29 Statins are also under investigation in human patients as agents to decrease renal injury. 30 These drugs, or other means of lipid modulation, also may prove beneficial in dogs.…”

Section: Discussionmentioning

confidence: 99%

Serum Lipoprotein Changes in Dogs with Renal Disease

Behling‐Kelly

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundPeople with renal disease develop a dyslipidemia that contributes to progression of renal injury and development of cardiovascular disease. Lipoproteins in dogs with renal disease have not been investigated.HypothesisDogs with chronic kidney disease (CKD) have dyslipidemia characterized by increased lower density lipoproteins and decreased high‐density lipoproteins (HDLs). The degree of dyslipidemia is positively correlated with severity of disease, as reflected by serum creatinine concentration.AnimalsProspective study of client‐owned dogs presented to the Cornell University Hospital for Animals: 29 dogs with confirmed CKD, 5 dogs with nephrotic syndrome (NS), and 12 healthy control dogs presented for routine vaccinations, dental cleaning, or owned by students.MethodsLipoprotein electrophoresis was used to quantify relative proportions of the 3 main classes of lipoproteins in canine serum: low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL), and HDL. Serum cholesterol and creatinine concentrations; urinalysis and urine protein‐to‐creatinine ratio were measured by standard methods.ResultsDyslipidemia was consistently found in dogs with CKD and NS and was characterized by a decrease in HDL and variable increases in LDL and VLDL. Dogs with NS had a proportionately greater increase in the VLDL fraction, as compared with dogs with CKD.Conclusion and Clinical ImportanceDyslipidemia similar to that documented in people with renal disease occurs in dogs with CKD, despite serum cholesterol concentrations often being within the reference interval. The contribution of altered lipoproteins to the pathogenesis of renal disease in dogs warrants additional study.

show abstract

“…It can occur as a complication of CRF as a result of ROD. [4][5][6][7][8][9][10][11] ROD is a frequent long-term complication of renal disease that can induce a broad spectrum of bone metabolism disorders associated with different pathogenic pathways. The symptoms of ROD comprise bone demineralization with trabeculation and cortical loss, giant cell radiotransparencies, or metastatic calcifications of the soft tissues.…”

Section: Case Reportmentioning

confidence: 99%

Oral Manifestations of Renal Osteodystrophy in a Patient with Systemic Lupus Erythematosus with Chronic Renal Failure and Systemic Lupus Erythematosus with Chronic Renal Failure and Secondary Hyperparathyroidism: A Case Report Secondary Hyperparathyroidism: A Case Rep

Riyachan¹,

Subarnbhesaj²,

Sarideechaigu³

et al. 2019

J Dent Indones

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is one of the chronic autoimmune diseases that leads to multiple manifestations in several organ systems, including chronic renal failure (CRF). Renal osteodystrophy (ROD) is one of the most common complications of CRF associated with secondary hyperparathyroidism (HPT). A combination of CRF and HPT can result in broad-spectrum disorders in the metabolism of minerals such as calcium, phosphorus, and vitamin D, which can affect bone turnover, mineralization, and volume. Radiographic alterations of ROD are considered as one of the earliest signs of CRF. Objective: To describe the oral manifestations in both the maxilla and mandible of a patient with ROD resulting from SLE with CRF and secondary HPT. Case report: A 37-yearold female patient visited the Faculty of Dentistry, Khon Kaen University, for the management of traumatic ulcers on the left and right buccal mucosa and generalized maxillary and mandibular bony hard swellings with mild paresthesia in the lower left mandible for a period of 4 months. The patient had been suffering from SLE for approximately 20 years. However, secondary HPT and CRF as consequences of refractory SLE were being treated concomitantly. Intraoral examination showed several nonpainful ulcers on the left and right buccal mucosa. Radiographic findings revealed generalized loss of lamina dura with thinning of cortical outlines of the maxilla and mandible. Due to complications associated with treatment and the general conditions of this patient, she was referred for treatment to a palliative care unit. Conclusion: Systemic symptoms and complications of patient with ROD with CRF and secondary HPT are seriously problematic. The role of the dentist in this case is to detect the disease, lessen the complications, and make the patient experience minimal pain and side effects in palliative care.How to cite this article: Riyachan I, Subarnbhesaj A, Sarideechaigul W, Klanrit P. Oral manifestations of renal osteodystrophy in a patient with systemic lupus erythematosus with chronic renal failure and secondary hyperparathyroidism: a case report. J Dent Indones. 2019;26(3):165-169.

show abstract

Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews

Abstract: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney disease and should be considered for such individuals who also present hyperlipidemia.

Cited by 3 publications

References 8 publications

Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I–IIIa chronic kidney disease: an observational cohort study in Taiwan

Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I–IIIa chronic kidney disease: an observational cohort study in Taiwan

Serum Lipoprotein Changes in Dogs with Renal Disease

Oral Manifestations of Renal Osteodystrophy in a Patient with Systemic Lupus Erythematosus with Chronic Renal Failure and Systemic Lupus Erythematosus with Chronic Renal Failure and Secondary Hyperparathyroidism: A Case Report Secondary Hyperparathyroidism: A Case Rep

Contact Info

Product

Resources

About